Miguel
Fernández de Sanmamed Gutiérrez
Consultor Médico
Fundación Jiménez Díaz
Madrid, EspañaPublications in collaboration with researchers from Fundación Jiménez Díaz (1)
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229